Immuneering to Present at the Leerink Global Healthcare Conference
Immuneering (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, March 9-11, 2026.
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, March 9-11, 2026. CEO Ben Zeskind will deliver a fireside chat and hold 1x1 investor meetings on March 9, 2026, 3:40–4:10 pm ET.
The presentation will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IMRX
In the Mar 3 session, IMRX declined 1.00%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference dates
- March 9–11, 2026
- Leerink Global Healthcare Conference in Miami, Florida
- Presentation time
- 3:40–4:10 pm ET
- Immuneering fireside chat on March 9, 2026
- Shelf registration
- $300,000,000
- Total securities registered under Form S-3 shelf
- ATM capacity
- $100,000,000
- Potential Class A common stock sales via Piper Sandler under shelf
Historical Context
-
Oppenheimer healthcare conference presentation with webcast and 1x1 investor meetings.
-
Updated Phase 2a pancreatic cancer data showing strong 12-month survival metrics.
-
Announcement of upcoming webcast to present 12‑month overall survival results.
-
Secured FDA and EMA alignment for global Phase 3 MAPKeeper 301 trial design.
-
Expected addition to the Nasdaq Biotechnology Index prior to December 22, 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.